InflaRx (NASDAQ:IFRX) Short Interest Up 36.8% in March

InflaRx (NASDAQ:IFRX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 794,600 shares, an increase of 36.8% from the March 15th total of 581,000 shares. Based on an average daily volume of 391,800 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.4% of the company's shares are sold short.

Hedge Funds Weigh In On InflaRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new position in InflaRx in the fourth quarter worth approximately $1,576,000. Commonwealth Equity Services LLC lifted its position in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock worth $275,000 after purchasing an additional 19,000 shares during the last quarter. Northern Trust Corp grew its stake in shares of InflaRx by 1,933.1% during the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company's stock worth $1,647,000 after purchasing an additional 634,045 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in InflaRx in the fourth quarter valued at $55,000. Finally, Geode Capital Management LLC raised its stake in InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after buying an additional 11,900 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Stock Up 1.0 %

InflaRx stock traded up $0.01 during mid-day trading on Friday, reaching $1.06. 48,132 shares of the company's stock were exchanged, compared to its average volume of 224,634. The company has a fifty day moving average of $1.32 and a 200-day moving average of $1.83. The company has a market cap of $71.16 million, a P/E ratio of -0.98 and a beta of 2.21. InflaRx has a twelve month low of $0.82 and a twelve month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. Equities research analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on IFRX. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday, March 21st. Guggenheim lifted their target price on InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.